Join
Live feed
·
PRReleasevia Quantisnow
NextCure Inc. logo

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

ByQuantisnow·Wall Street's wire, on your screen.
NXTC· NextCure Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NXTC (NextCure Inc.) and more on Quantisnow.